Collegium Pharmaceutical (NASDAQ:COLL) Reaches New 12-Month High – Here’s What Happened

Shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) reached a new 52-week high on Friday . The stock traded as high as $50.00 and last traded at $49.9750, with a volume of 203913 shares. The stock had previously closed at $49.58.

Analyst Ratings Changes

Several research firms have commented on COLL. Barclays initiated coverage on shares of Collegium Pharmaceutical in a report on Monday, December 8th. They set an “overweight” rating and a $58.00 price objective on the stock. Truist Financial boosted their price target on shares of Collegium Pharmaceutical from $45.00 to $48.00 and gave the company a “buy” rating in a research report on Friday, November 7th. Weiss Ratings restated a “buy (b-)” rating on shares of Collegium Pharmaceutical in a research note on Monday, December 22nd. Wall Street Zen upgraded shares of Collegium Pharmaceutical from a “buy” rating to a “strong-buy” rating in a research note on Saturday, November 8th. Finally, Needham & Company LLC reissued a “buy” rating and set a $46.00 target price on shares of Collegium Pharmaceutical in a report on Tuesday, October 28th. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has given a Hold rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus price target of $47.00.

Collegium Pharmaceutical Stock Performance

The business’s fifty day moving average is $43.93 and its 200-day moving average is $37.34. The company has a quick ratio of 1.27, a current ratio of 1.36 and a debt-to-equity ratio of 2.71. The company has a market cap of $1.58 billion, a PE ratio of 30.96 and a beta of 0.61.

Collegium Pharmaceutical (NASDAQ:COLL) last issued its quarterly earnings data on Wednesday, September 4th. The specialty pharmaceutical company reported $1.26 earnings per share (EPS) for the quarter. Collegium Pharmaceutical had a net margin of 7.72% and a return on equity of 102.03%. The firm had revenue of $135.55 million during the quarter. As a group, research analysts predict that Collegium Pharmaceutical, Inc. will post 5.62 EPS for the current fiscal year.

Insider Activity

In related news, CFO Colleen Tupper sold 30,000 shares of the stock in a transaction that occurred on Thursday, November 6th. The shares were sold at an average price of $40.53, for a total value of $1,215,900.00. Following the completion of the sale, the chief financial officer directly owned 126,667 shares of the company’s stock, valued at approximately $5,133,813.51. This represents a 19.15% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Scott Dreyer sold 17,600 shares of the company’s stock in a transaction that occurred on Monday, December 8th. The stock was sold at an average price of $48.17, for a total transaction of $847,792.00. Following the completion of the transaction, the executive vice president owned 103,613 shares of the company’s stock, valued at approximately $4,991,038.21. The trade was a 14.52% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 51,250 shares of company stock valued at $2,235,352 in the last ninety days. Corporate insiders own 2.51% of the company’s stock.

Institutional Trading of Collegium Pharmaceutical

Institutional investors and hedge funds have recently bought and sold shares of the stock. Federated Hermes Inc. raised its position in Collegium Pharmaceutical by 67.0% during the third quarter. Federated Hermes Inc. now owns 872 shares of the specialty pharmaceutical company’s stock valued at $31,000 after purchasing an additional 350 shares during the period. CWM LLC raised its holdings in Collegium Pharmaceutical by 453.9% during the 2nd quarter. CWM LLC now owns 1,407 shares of the specialty pharmaceutical company’s stock valued at $42,000 after buying an additional 1,153 shares during the period. Hantz Financial Services Inc. raised its holdings in Collegium Pharmaceutical by 137.7% during the 3rd quarter. Hantz Financial Services Inc. now owns 1,714 shares of the specialty pharmaceutical company’s stock valued at $60,000 after buying an additional 993 shares during the period. EverSource Wealth Advisors LLC lifted its position in Collegium Pharmaceutical by 744.9% in the second quarter. EverSource Wealth Advisors LLC now owns 2,484 shares of the specialty pharmaceutical company’s stock worth $73,000 after buying an additional 2,190 shares during the last quarter. Finally, GAMMA Investing LLC boosted its stake in Collegium Pharmaceutical by 368.9% during the second quarter. GAMMA Investing LLC now owns 2,757 shares of the specialty pharmaceutical company’s stock worth $82,000 after buying an additional 2,169 shares during the period.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on the development, manufacture and commercialization of products for pain management and opioid dependence. The company’s core expertise lies in its DETERx microsphere technology, a platform designed to provide extended-release delivery of active pharmaceutical ingredients while deterring manipulation for unintended routes of abuse.

The company’s principal marketed products include Xtampza® ER (extended-release oxycodone), which received approval from the U.S.